Abstract-Vascular endothelial growth factor
V ascular endothelial growth factor (VEGF) has been recognized as an angiogenic factor that induces endothelial proliferation and vascular permeability. 1 It may play a role in tumor growth, wound healing, age-related macular degeneration, rheumatoid arthritis, diabetic retinopathy, and collateral formation in ischemic tissue. However, recent studies have demonstrated that the gene for the VEGF receptor flt-1 is also expressed in human monocytes and that the VEGF-induced chemotactic response of human monocytes is mediated via this receptor. 2 Clauss et al 3 have also documented that VEGF induces monocyte activation and migration. These data strongly suggest that VEGF plays a role in the chemotaxis of monocytes/macrophages, which is crucial in inflammatory reactions and in wound-repair processes. We and others have reported that VEGF is remarkably expressed in activated macrophages, endothelial cells, and smooth muscle cells within human coronary atherosclerotic lesions, and we have proposed the significance of VEGF in the progression of atherosclerosis. 4 -7 Oxidized LDL (Ox-LDL) has been demonstrated to be a key molecule in the atherosclerotic process. 8, 9 It has been reported that Ox-LDL, which abundantly exists in atherosclerotic arterial walls, plays an important role in endothelial functional alterations, the recruitment and retention of mono-cyte/macrophages, and foam cell formation. 10 -12 It has been also revealed that Ox-LDL modulates the secretion of cytokines or growth factors from endothelial cells and macrophages. 13, 14 In this context, we hypothesized that Ox-LDL might play a role in the expression of VEGF in injured endothelial cells or accumulated macrophages in atherosclerotic lesions. In the present study, to clarify the mechanism of VEGF expression in atherosclerotic lesions, we examined the regulation of VEGF expression in endothelial cells and macrophages by Ox-LDL.
Peroxisome proliferator-activated receptor-␥ (PPAR␥) is a member of the nuclear receptor superfamily of ligand-activated transcription factors. 15 PPAR␥ and retinoid X receptor contain the heterodimer to bind regulatory elements in the promoter region of a number of adipocyte-specific genes and to stimulate transcription in response to PPAR␥-specific and retinoid X receptor-specific ligands. 16, 17 PPAR␥ mRNA is most highly expressed in adipose tissue and plays an important role in regulating adipocyte differentiation and glucose metabolism. 18 A new class of antidiabetic agents, thiazolidinediones, have been developed and have been demonstrated to improve insulin resistance by binding and activating PPAR␥. 19 -21 Recently, Tontonoz et al 22 have reported that PPAR␥ is expressed not only in adipocytes but also in monocytes/macrophages, and they have suggested that PPAR␥ may have a role in the differentiation of monocytes/macrophages. Moreover, they have identified 2 of the major oxidized lipid components of Ox-LDL, 9-hydroxy-(S)-10,12-octadecadienoic acid (9-HODE) and 13-hydroxy-(S)-10,12-octadecadienoic acid (13-HODE), as endogenous activators and ligands of PPAR␥. 23 PPAR␥ expression in human endothelial cells has also been revealed. 24 Thus, we sought to determine whether PPAR␥ might work through the pathway of regulation of VEGF expression in endothelial cells and macrophages stimulated by Ox-LDL. In the present study, we further investigate the regulation of VEGF expression by Ox-LDL in macrophages and endothelial cells via the possible activation of PPAR␥ activators.
Methods Agents
Troglitazone (TRO) was obtained from Sankyo; 15-deoxy-⌬ 12,14 -prostaglandin J 2 (PGJ2), prostaglandin F 2␣ (PGF 2␣ ), 9-HODE, and 13-HODE were purchased from Cayman. LDL (Sigma Chemical Co) was dialyzed against 3 changes of PBS to remove EDTA. Then LDL was oxidized at a concentration of 500 g/mL by exposure to 10 mol/L CuSO 4 for 24 hours at room temperature, followed by dialysis at 4°C for 24 hours against 3 changes of PBS. 12, 14, 25 We designated LDL incubated with CuSO 4 for 5 hours as minimum modified LDL (mm-LDL) and LDL incubated for 24 hours as Ox-LDL. The extent of lipid peroxidation was estimated by electrophoresis in agarose gel.
Cell Culture
Human monocytic leukemia (THP-1) cells and human monoblastic leukemia (U937) cells were obtained from the American Tissue Culture Collection and cultured in RPMI 1640 medium (GIBCO-BRL) with 10% FBS at 37°C in 5% CO 2 . Cells were cultured in serum-free medium just before the experiments. The U937 cell line permanently expressing PPAR␥ was established as follows: PPAR␥1 expression vector, pCMX-mPPAR␥, 26 possessing cytomegalovirus enhancer and mouse full-length PPAR␥1 cDNA 27 (1.4 kb, GenBank No. U10374), which was kindly donated by Prof K. Umesono (Kyoto University Graduate School of Medicine), and 10 mg neomycin resistance gene plasmid expression vector (pCXNNeo) 28 were cotransfected to U937. Electroporation was performed by using a Bio-Rad Gene Pulser set at 220 V and 960 mF. Neomycin (GIBCO-BRL) was added to a final concentration of 1 g/mL. Individual clones were isolated by seeding transfected cells at a limiting dilution in 96-well plates in the medium containing 20% FBS. We designated this U937 cell line expressing PPAR␥ as U937T cells. Human coronary artery endothelial cells (HCAECs) were purchased from Clonetics, and they were cultured in EGM-2MV (endothelial cell growth medium; Clonetics) with 5% FCS and changed to serum-free medium just before the experiments.
RNA Extraction, Northern Blot Analysis, and RT-PCR
Total cellular RNA was isolated from HCAECs and THP-1 cells by using TRIzol reagents (GIBCO-BRL). RNA (20 g per lane) was electrophoresed on 1% agarose/6% formaldehyde gels and transferred to nylon membranes (Biodyne, Pall BioSupport). Hybridization was performed at 42°C for 20 hours in 50% formamide, 5ϫ SSC, 0.05 mol/L phosphate buffer, 5ϫ Denhardt's solution, 0.1% SDS, 0.1 mg/mL denatured salmon sperm DNA, and 1ϫ10 9 cpm/mL 32 P-labeled cDNA probes. A 320-bp PstI-EcoRI fragment (nucleotides 484 to 501) of rat VEGF189 cDNA was used as a probe. After hybridization, the filters were washed in 1ϫ SSC/0.1% SDS for 10 minutes at room temperature, for 30 minutes at 55°C, and then in 0.1ϫ SSC/0.1% SDS for 30 minutes at 55°C. Filters were autoradiographed, and the resulting bands were quantified by the BAS 2000 system (Fuji Photo Film Co, Ltd). Reverse transcriptase (RT)-polymerase chain reaction (PCR) for VEGF mRNA was performed as follows 5 : cDNA was synthesized from 5 g of total RNA primed with oligo-dT by use of RT (Super Script II) at 42°C for 1 hour. cDNA (0.5 g) was subjected to PCR with 50 fmol of primers. Primer sequences were 5Ј-GGACATCTTCCAGGAGTA-3Ј (human VEGF 165 cDNA nucleotides 232 to 250) and 5Ј-TGCAACGCGAGTCTGTGT-3Ј (nucleotides 555 to 573) for detecting human VEGF mRNA. Amplification was carried out for 30 cycles with 30 seconds of incubation at 94°C, 30 seconds at 55°C, and 1 minute at 72°C. A 10-L aliquot of each RT-PCR reaction mixture was electrophoresed on a 1.5% agarose gel.
VEGF Protein Quantification
After incubation of the THP-1, U293, and U293T under the indicated conditions, the conditioned medium was collected and centrifuged at 100g for 5 minutes, and the supernatant was used for the measurement of VEGF protein with a Quantikine Human VEGF ELISA kit (R&D Systems, Inc). The sensitivity of the assay was 1 pg/mL. All samples were measured in duplicate.
Immunohistochemical Staining
HCAECs were cultured by use of flexiPERM (Heraeus Instruments), and before staining, they were permeabilized by Triton-X (Nakarai Tesque). For the identification of VEGF, a rabbit polyclonal antibody that was directed against the 20 amino terminal residues of human VEGF (Santa Cruz Biotechnology) was used. Immunohistochemical staining was performed by the LSAB (labelled streptavidin-biotin) method as described. 5 
Western Blotting
Nuclear extracts of THP-1, U937, and U937T cells were obtained as described. 29 Samples were applied to 10% SDS gels and transferred to nitrocellulose membranes (Bio-Rad) by using semidry blotting. Anti-PPAR␥ polyclonal antibody was a kind gift from Dr Heidi Camp (Pfizer Inc, Ann Arbor, Mich). 29 Membranes were incubated with the antibody at a dilution of 1:1000 for 2 hours. After they were washed, the membranes were stained with horseradish peroxidaseconjugated rabbit anti-goat antibody. Antigen detection was performed with a CSL kit (Amersham-Pharmacia).
Statistical Analysis
All results were expressed as meanϮSD. Statistical analyses of the data were performed by ANOVA. A value of PϽ0.05 was considered significant. The experiments presented were the representatives of at least 2 separate experiments.
Results

Ox-LDL Increases VEGF Expression in Endothelial Cells and Monocytes/Macrophages
We have previously reported that human endothelial cells express VEGF in atherosclerotic lesions. 5 We examined whether Ox-LDL stimulates VEGF expression in HCAECs. As shown in Figure 1A , Ox-LDL (10 to 50 g/mL) increased VEGF mRNA expression in HCAECs in a time-dependent manner. When HCAECs were exposed to 10 to 50 g/mL Ox-LDL for 6 hours, the VEGF mRNA level increased in a dose-dependent manner ( Figure 1B) . In contrast, native LDL at the same concentration had no effect on VEGF mRNA levels. We also used immunohistochemical techniques to examine whether VEGF was present in cultured HCAECs. As shown in Figure 1C , strong positive staining for VEGF was observed in HCAECs cultured with 100 g/mL Ox-LDL for 12 hours. Native LDL had no effect on VEGF staining. No evidence of a toxic effect of Ox-LDL was observed during the incubation with HCAECs, as assessed by morphology and trypan blue exclusion.
THP-1 cells were exposed to Ox-LDL at concentrations between 10 and 50 g/mL for 24 hours. VEGF levels were determined in culture medium by ELISA. VEGF concentration was increased significantly by exposure to Ox-LDL (for VEGF concentration, vehicle was 548.7Ϯ28.4 pg/mL, 10 g/mL Ox-LDL was 742.0Ϯ26.7 pg/mL [PϽ0.05 versus vehicle], and 50 g/mL Ox-LDL was 1078.9Ϯ100.6 pg/mL [PϽ0.05 versus vehicle]). Native LDL had no effect on VEGF protein levels (599.1Ϯ3.3 pg/mL). No evidence of a toxic effect of Ox-LDL was observed during the incubation with THP-1 cells.
PPAR␥ Activators Increase VEGF Expression in Endothelial Cells and Monocytes/Macrophages
HCAECs were exposed to TRO (10 Ϫ7 to 10 Ϫ5 mol/L). As shown in Figure 2A , VEGF mRNA expression was upregulated by TRO in a dose-dependent manner (percent over the control, 10 Ϫ7 mol/L TRO 159%, 10 Ϫ6 mol/L TRO 193%, and 10 Ϫ5 mol/L TRO 250%) The mRNA expression of VEGF in THP-1 was also dose-dependently augmented by TRO and PGJ2 at 10
Ϫ5 mol/L PGJ2 168%, and 12-0-tetradecanoylphorbol-13-acetate [TPA] 203%; Figure 2B ). In contrast, VEGF expression in U937 was not augmented by TRO or PGJ2 (data not shown). As shown in Figure 2C , RT-PCR analysis also confirmed that TRO (10 Ϫ5 mol/L) as well as lysophosphatidylcholine (LPC, 10 Ϫ5 mol/L), which is one of the major components of Ox-LDL, increased VEGF mRNA expression. The augmentation of VEGF mRNA expression by TRO or LPC in THP-1 cells was not observed in the presence of actinomycin D, the inhibitor of transcription.
PPAR␥ Activators Increase VEGF Protein Levels in Culture Medium
To examine whether PPAR␥ activators stimulate VEGF production by THP-1 cells, VEGF levels were determined by Figure 3A ). TRO and PGJ2 stimulated VEGF production by THP-1 cells in a concentration-dependent manner ( Figure 3B and 3C ). In the culture medium collected after treatment with 10 mol/L TRO, the VEGF concentration was 3.9-fold higher than that of control ( Figure 3B ). We further examined the effect of PGF 2␣ , an agent known to inhibit PPAR␥ activation, 30 on TRO-induced secretion of VEGF from THP-1. The addition of PGF 2␣ (200 nmol/L) significantly decreased the effect of TRO on VEGF secretion ( Figure 3D ).
Ox-LDL Upregulates VEGF Expression Partly Through PPAR␥ Activation
To further characterize the role of PPAR␥ in Ox-LDLregulated VEGF expression in monocytes/macrophages, we established the permanent cell line of U937 expressing PPAR␥ (U937T cells). As shown in Figure 4A , in U937T cells, TRO treatment resulted in a marked upregulation of VEGF secretion similar to that in THP-1 cells, whereas it had no effect on VEGF secretion from U937 cells. As shown in Figure 4B , PPAR␥ expression in THP-1 cells was barely detected by Western blot, but after TRO or TPA stimulation, we could detect the expression of PPAR␥ in THP-1 cells. U937T cells showed significant PPAR␥ expression, whereas U937 cells did not. Figure 5 shows the responsiveness of THP-1, U937, and U937T cells to Ox-LDL. VEGF secretion from these cell lines was significantly upregulated by Ox-LDL stimulation with different magnitudes. VEGF secretion from U937T cells was increased to 190% and 212% by 10 and 50 g/mL Ox-LDL stimulation, respectively, whereas the secretion from THP-1 cells was increased to 135% and 197% by Ox-LDL at 10 and 50 g/mL, respectively. The increase of VEGF secretion from U937 cells by Ox-LDL (50 g/mL) was only 125% of the control value. These differences suggest that PPAR␥ plays some role in the VEGF expression in THP-1 cells induced by Ox-LDL.
9-HODE and 13-HODE Regulate VEGF Secretion From Human Macrophage Cell Lines
Two of the major oxidized lipid components of Ox-LDL, 9-HODE and 13-HODE, were reported to be endogenous activators and ligands of PPAR␥. Thus, we investigated whether 9-HODE and 13-HODE could stimulate VEGF production by human macrophage cell lines. As shown in Figure 6 , VEGF production by THP-1 cells was increased by exposure to 9-HODE and 13-HODE (0.1 to 5 g/mL) for 24 hours, but VEGF production by U937 cells, in which we could not detect PPAR␥ mRNA, was not increased by 9-HODE or 13-HODE. The result further supports the possibility that Ox-LDL induces VEGF expression through PPAR␥ activation. In addition, LPC also stimulated VEGF production by U937 cells.
Discussion
We and others have previously demonstrated the expression of VEGF protein and mRNA in the progression of human coronary atherosclerosis. 4 -7 We have reported that VEGF is remarkably expressed in activated macrophages, endothelial cells, and smooth muscle cells within human coronary atherosclerotic lesions and proposed the significance of VEGF in the progression of atherosclerosis. Because Ox-LDL is abundant in atherosclerotic arterial walls and is critically involved in atherogenesis, we hypothesized that Ox-LDL might have a role in the expression of VEGF in atherosclerotic lesions. Ramos et al 6 have previously reported the induction of VEGF expression in a mouse macrophage-like cell line (RAW 264 cells) in response to Ox-LDL. The present study was compatible with their result and further revealed that Ox-LDLinduced upregulation of VEGF occurred not only in macrophages but also in endothelial cells.
The significance of PPAR␥ in atherosclerosis is beginning to be elucidated. It is reported that PPAR␥ activators inhibit neointimal formation after balloon injury of the rat carotid artery. 31 Recently, many lines of evidence have elucidated that PPAR␥ regulates the expression of several genes important not only for lipid metabolism but also for atherogenesis. 15, 31, 32 We have reported that PPAR␥ activators regulate monocyte migration. 33 We have also revealed that PPAR␥ activators modulate endothelial cell growth and secretion of endothelin-1 and C-type natriuretic peptide. 34 In the present study, we showed that PPAR␥ ligands, TRO and PGJ2, upregulated VEGF expression in HCAECs and THP-1 cells, which express PPAR␥. Furthermore, the effects of TRO on VEGF mRNA expression in THP-1 cells were not seen in the presence of actinomycin D. This result suggests that the increase of the VEGF mRNA level by TRO was at the transcriptional level. In contrast, they had no effect on VEGF expression in wild-type U937 cells, which lack the expression of PPAR␥. We have further demonstrated that the U937 cell line, which stably expresses PPAR␥, restores the responsiveness of VEGF expression to TRO . In addition, PGF 2␣ , which has been shown to inhibit phosphorylation of PPAR␥ and exert inhibition on PPAR␥ activation, 30 significantly suppressed the effect of TRO on VEGF secretion from THP-1 cells. Taken together, it is likely that PPAR␥ activation can cause the induction of VEGF expression.
However, it remains unclear how PPAR␥ upregulates VEGF gene expression. We searched the promoter region of the VEGF gene but could not find the direct repeat sequence of the PPAR␥ responsive element. Recently, many coactivators, such as CBP/p300 and PPAR binding protein, which interact with multiple ligand-bound nuclear receptors and facilitate their transactivation, have been isolated. 35, 36 The interaction with PPAR␥ and these coactivators may have influences on the effect of other transcriptional factors, which require these coactivators. Elucidation of the mechanism of PPAR␥-dependent regulation of VEGF gene expression requires further investigation.
PPAR␥ is activated by the lipid components of Ox-LDL (9-HODE and 13-HODE) and PGJ2. 22, 23 9-HODE and 13-HODE have been shown to promote the differentiation of human monocytes to macrophages and to facilitate Ox-LDL uptake through transcriptional induction of the scavenger receptor CD36. Thus, we hypothesized that VEGF expression in endothelial cells and macrophages stimulated by Ox-LDL is regulated through the activation of PPAR␥. There are only a few reports concerning the significance of Ox-LDL and its components, 9-HODE and 13-HODE, as natural ligands of PPAR␥. Chen et al 37 have reported that the PPAR␥ agonists enhance endothelial cell adhesiveness by increasing intercellular adhesion molecule-1 (ICAM-1) expression. They have shown that ICAM-1 expression is upregulated by the PPAR␥ ligand TRO and also by Ox-LDL as well as 13-HODE and have suggested that the PPAR␥ signaling pathway might contribute to the regulation of ICAM-1 and atherogenicity of Ox-LDL. In the present study, we have demonstrated the upregulation of VEGF expression in macrophages stimulated by 9-HODE and 13-HODE. Moreover, we have observed that U937T cells, which permanently express PPAR␥, show responsiveness to Ox-LDL stimulation similar to that in THP-1 cells, which express PPAR␥. These data strongly suggest that VEGF expression in endothelial cells and macrophages stimulated by Ox-LDL is regulated, at least in part, through the activation of PPAR␥.
Ramos et al 6 have shown that LPC also upregulates VEGF expression in RAW 264 cells. We have observed that LPC also induces VEGF expression in HCAECs. 38 As shown in Figure 5 , Ox-LDL stimulated VEGF secretion in U937 cells with less magnitude. Inasmuch as we observed significant stimulation by LPC of VEGF expression in U937 cells ( Figure 2C and 6) , LPC is also involved in Ox-LDLregulated VEGF expression.
The exact role of VEGF in atherosclerotic lesions remains to be determined. It has been reported that the in vivo introduction of human VEGF165 cDNA into rabbit carotid arteries, by use of the hemagglutinating virus of Japanliposome method, induces prominent angiomatoid proliferation of endothelial cells and thickening of the intima due to fibromuscular hyperplasia. 39 Angiogenesis in atheromatous plaques is suggested to be an important process of atherogenesis and plaque rapture. 40, 41 Thus, VEGF produced in accumulating macrophages in atheromatous plaque could have a proatherogenic effect. On the other hand, VEGF can also play a role in protecting endothelial cells from injury in the early phase of atherosclerosis. 42 Upregulation of VEGF expression by Ox-LDL, the key molecule of atherosclerosis, through the PPAR␥ activation observed in the present study can be relevant in the progression of atherosclerosis.
In conclusion, we have shown that Ox-LDL regulates VEGF expression in human atherosclerotic lesions through, at least in part, ligand activation of PPAR␥. These findings suggest that the PPAR␥ signaling pathway may play a role in atherogenesis induced by Ox-LDL.
